News Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
64.57 ^USD	+0.03%		+0.17%	+238.77%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN	Apr. 17	PR
North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	Apr. 16	MT
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN	Apr. 12	BU
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform	Apr. 12	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	Apr. 11	AQ
Wall Street rebounds on softer inflation data, eyes on earnings	Apr. 11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform	Apr. 11	MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
Nasdaq set for higher open as fresh inflation data allays rate jitters	Apr. 11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50	Apr. 11	MT
Guggenheim Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $55	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Summary

Filters